Literature DB >> 22284028

Radiotherapy for liver metastases: a review of evidence.

Morten Høyer1, Anand Swaminath, Sean Bydder, Michael Lock, Alejandra Méndez Romero, Brian Kavanagh, Karyn A Goodman, Paul Okunieff, Laura A Dawson.   

Abstract

Over the past decade, there has been an increasing use of radiotherapy (RT) for the treatment of liver metastases. Most often, ablative doses are delivered to focal liver metastases with the goal of local control and ultimately improving survival. In contrast, low-dose whole-liver RT may be used for the palliation of symptomatic diffuse metastases. This review examines the available clinical data for both approaches. The review found that RT is effective both for local ablation of focal liver metastases and for palliation of patients with symptomatic liver metastases. However, there is a lack of a high level of evidence from randomized clinical trials.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22284028     DOI: 10.1016/j.ijrobp.2011.07.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  59 in total

Review 1.  Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions.

Authors:  Anand Swaminath; William Chu
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy.

Authors:  Sam S Yoon; Thomas A Aloia; Alex B Haynes; Avinash Kambadakone; Harmeet Kaur; Jean-Nicolas Vauthey; Cristina R Ferrone; Andrew X Zhu; Jennifer Y Wo; Christopher Crane; Theodore S Hong
Journal:  Pract Radiat Oncol       Date:  2013-08-29

3.  Increasing use of advanced radiation therapy technologies in the last 30 days of life among patients dying as a result of cancer in the United States.

Authors:  B Ashleigh Guadagnolo; Kai-Ping Liao; Sharon H Giordano; Linda S Elting; Thomas A Buchholz; Ya-Chen Tina Shih
Journal:  J Oncol Pract       Date:  2014-04-22       Impact factor: 3.840

Review 4.  Stereotactic body radiation therapy for liver metastases.

Authors:  Marta Scorsetti; Elena Clerici; Tiziana Comito
Journal:  J Gastrointest Oncol       Date:  2014-06

Review 5.  Non-operative therapies for colorectal liver metastases.

Authors:  John L Nosher; Inaya Ahmed; Akshar N Patel; Vyacheslav Gendel; Philip G Murillo; Rebecca Moss; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2015-04

6.  The utility of positron emission tomography/computed tomography in target delineation for stereotactic body radiotherapy for liver metastasis from primary gastric cancer: an illustrative case report and literature review.

Authors:  Gary D Lewis; Stephen B Chiang; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2017-06

7.  Stereotactic body radiation therapy for liver metastasis - The linac-based Greater Poland Cancer Centre practice.

Authors:  Magdalena Fundowicz; Marta Adamczyk; Anna Kołodziej-Dybaś
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-04

Review 8.  Endoluminal and Interstitial Brachytherapy for the Treatment of Gastrointestinal Malignancies: a Systematic Review.

Authors:  Sujana Gottumukkala; Vasu Tumati; Brian Hrycushko; Michael Folkert
Journal:  Curr Oncol Rep       Date:  2017-01       Impact factor: 5.075

Review 9.  Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.

Authors:  Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-10-11       Impact factor: 6.113

Review 10.  Treatment of metastatic liver tumors using stereotactic ablative radiotherapy.

Authors:  Vimoj J Nair; Jason R Pantarotto
Journal:  World J Radiol       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.